SynthesisSystematic reviews2025
Prevalence and molecular epidemiology of carbapenem resistance in Asia: a systematic review and meta-analysis.
Synthesis in Systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Prevalence and molecular typing of carbapenem-resistant Enterobacterales in a secondary-care hospital in Jazan region, Saudi Arabia.New microbes and new infections · 2026Article
- Antimicrobial susceptibility of priority bacterial pathogens from laboratory samples in Timor-Leste: a retrospective analysis of database (2020-2025).The Lancet regional health. Southeast Asia · 2026Article
- Bacterial profile and antimicrobial resistance in patients with pulmonary infection: a retrospective tertiary hospital-based study.BMC infectious diseases · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Role of Mobilome in Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Clinically Significant Carbapenemases in Gram-Negative Pathogens: Molecular Diversity and Advances in β-Lactamase Inhibitor Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Case report: rapid in vivo resistance mechanism shifts in multiple carbapenem-resistant Pseudomonas aeruginosa strains after esophagectomy in an immunocompromised patient: a case report.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Temporal dynamics and predictors of carbapenem-resistant gram-negative bacteria in bloodstream infections in hematological patients.BMC infectious diseases · 2026Article
- Evaluating long-read metagenomics for bloodstream infection diagnostics: a pilot study from a Thai Tertiary Hospital.Scientific reports · 2026Article
- Dissemination of integrons and carbapenemase-encoding genes among multidrug resistant Proteus mirabilis isolated from urinary tract infections in Egypt.BMC infectious diseases · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenems are a group of last-resort antibiotics used to treat serious life-threatening infections. The emergence of resistance to carbapenems is a major public health threat. However, comprehensive information on the prevalence and molecular epidemiology of carbapenem resistance (CR) among Asian countries is lacking. Therefore, we aimed to determine the prevalence of CR and associated molecular determinants quantitatively among Asian countries.
methodsIn this systematic review and meta-analysis, we searched published reports in electronic databases such as PubMed, ScienceDirect, the Cochrane Library, and Web of Science from 1
resultsWe identified 2518 eligible studies, of which 37 assessed the CR prevalence data of 10,433 patients. The pooled prevalence (PPr) of CR was 31.3% (95% CI: 0.22 to 0.40; I
conclusionThe results suggest that surveillance of CR among Asian countries is essential to reduce the burden of antibiotic resistance. Mitigating the impact of CR infections will safeguard the efficacy of carbapenems for future generations and reduce further dissemination of CR genes. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42024515806.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.